CXCL2 and pneumonia: In 2017, Serebrovska et al. reported that treatment with CeO2NPs in a rat model of pneumonia significantly reduced lung tissue damage, ROS generation in both lung and blood, and expression of pro-inflammatory cytokines such as TNF-α, IL-6, and CxCL2 [40].